好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neutralizing Antibody Response to SARS-CoV-2 Vaccination in Multiple Sclerosis
Multiple Sclerosis
P11 - Poster Session 11 (11:45 AM-12:45 PM)
12-003

To investigate the humoral immune response following SARS-CoV-2 vaccination in patients with multiple sclerosis (pwMS) and to determine the effect of disease modifying therapies (DMT) on the vaccination response.  

Coronavirus disease 19 (COVD-19), a highly transmissible and potentially fatal illness caused by SARS-CoV-2, emerged as a global pandemic in early 2020. Several vaccines, including 2 innovative mRNA vaccines, were developed against this virus. 

To reduce relapse rates and slow disability accumulation, pwMS are often treated with DMTs which have anti-inflammatory properties and regulate adaptive immunity.  An important clinical issue concerns the impact of DMTs on the efficacy of SARS-CoV-2 vaccination, and the eventual need for booster doses. In this study, we measured the titers of anti-SARS-CoV-2 neutralizing antibodies (nAbs) in pwMS following SARS-CoV-2 vaccination.

We conducted a prospective longitudinal study in pwMS at the Ohio State University (OSU) MS Center. Longitudinal serum samples were obtained from pwMS prior to and after the administration of the SARS-CoV-2 vaccine. These samples were analyzed for nAbs against SARS-CoV-2 spike protein using a novel pseudotyped-lentivirus-based virus neutralization assay. OSU health care workers (HCWs) served as healthy controls. 
Of eighty-three consented subjects, fifty-two had post vaccination serum samples analyzed.  Although pwMS did not exhibit drastically different nAb titers compared to HCWs, 21% (n=11) did not have detectable nAb titers post-vaccination (NT50 < 40)—including 9 patients on B-cell depleting therapies, 1 on sphingosine 1-phosphate modulator, and 1 on no DMT. Compared to patients not on DMT, pwMS on B-cell depleting therapies exhibited 7-fold lower nAb titers, while those on fumarates or beta-interferon exhibited no significant difference to patients not on DMT.

Humoral immune response to the SARS-CoV-2 vaccine may be attenuated by certain DMTs, most notably B-cell depleting drugs. Further studies are underway to determine the effect of booster vaccine on nAb levels.
Authors/Disclosures
Tirisham Gyang, MD (Ohio State Univeristy, Wexner Medical Center, Department of Neurology)
PRESENTER 		Dr. Gyang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono.
No disclosure on file
Joseph S. Miller, MD Dr. Miller has stock in Google. Dr. Miller has stock in Meta. Dr. Miller has stock in Delta. Dr. Miller has stock in Nvidia. Dr. Miller has stock in Amazon.
Kariss M. Alcorn, MD (The Ohio State University) Mrs. Alcorn has nothing to disclose.
No disclosure on file
Erica Bell, PhD (The Ohio State University) Dr. Bell has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
Benjamin M. Segal, MD (Ohio State University, Dept of Neurology) Dr. Segal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bloom, Inc. Dr. Segal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lily. The institution of Dr. Segal has received research support from NIH. Dr. Segal has received intellectual property interests from a discovery or technology relating to health care. Dr. Segal has received intellectual property interests from a discovery or technology relating to health care. Dr. Segal has received personal compensation in the range of $5,000-$9,999 for serving as a Expert talks moderator; writer/ commentator with Ology Medical 好色先生, Inc/ Neurodiem.